anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided are systems and methods for blood pressure assessment using a wrist and cardiac device. In one embodiment, the wrist device receives a synchronization pulse, indicating cardiac onset, and generates blood-arrival signal data. In another embodiment, the wrist device receives cardiac signal data and generates blood-arrival signal data. The synchronization pulse or the cardiac signal data and the blood-arrival data are synchronized. The synchronization pulse or cardiac signal data and the blood-arrival signal data are processed to determine a pulse transit time between the heart and the wrist device. This pulse transit time and patient parameter are input into a trained neural network to generate an assessed blood pressure. The cardiac signal data can be generated by an electrical, acoustical, echocardiographic, or ballistocardiograph sensor. The blood-arrival signal data can be generated by an optical sensor, a tonometry sensor or a pressure-sensing sensor.
BACKGROUND: Asthma is a common obstructive airway disease with an inflammatory etiology. The main unmet need in the management of asthma is inadequate adherence to pharmacotherapy, leading to a poorly-controlled disease state, necessitating the development of novel therapies. Bronchom is a calcio-herbal formulation, which is purported to treat chronic asthma. The objective of the current study was to examine the in-vivo efficacy of Bronchom in mouse model of allergic asthma.
METHODS: Ultra high performance liquid chromatography was utilized to analyze the phytocompounds in Bronchom. Further, the in-vivo efficacy of Bronchom was evaluated in House dust mite (HDM)-induced allergic asthma in mice. Mice were challenged with aerosolized methacholine to assess airway hyperresponsiveness. Subsequently, inflammatory cell influx was evaluated in bronchoalveolar lavage fluid (BALF) followed by lung histology, wherein airway remodeling features were studied. Simultaneously, the levels of Th2 cytokines and chemokines in the BALF was also evaluated. Additionally, the mRNA expression of pro-inflammatory and Th2 cytokines was also assessed in the lung along with the oxidative stress markers.
RESULTS: Phytocompounds present in Bronchom included, gallic acid, protocatechuic acid, methyl gallate, rosmarinic acid, glycyrrhizin, eugenol, 6-gingerol and piperine. Bronchom effectively suppressed HDM-induced airway hyperresponsiveness along with the influx of leukocytes in the BALF. Additionally, Bronchom reduced the infiltration of inflammatory cells in the lung and it also ameliorated goblet cell metaplasia, sub-epithelial fibrosis and increase in α-smooth muscle actin. Bronchom decreased Th2 cytokines (IL-4 and IL-5) and chemokines (Eotaxin and IP-10) in the BALF. Likewise, it could also suppress the mRNA expression of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6 and IL-33), and IL-13. Moreover, Bronchom restored the HDM-induced diminution of endogenous anti-oxidants (GSH and SOD) and the increase in pro-oxidants (GSSG and MDA). Furthermore, Bronchom could also decrease the nitrosative stress by lowering the observed increase in nitrite levels.
CONCLUSION: Taken together, the results of the present study data convincingly demonstrate that Bronchom exhibits pharmacological effects in an animal model of allergic asthma. Bronchom mitigated airway hyperresponsiveness, inflammation and airway remodeling evoked by a clinically relevant allergen and accordingly it possesses therapeutic potential for the treatment of asthma.
In this study patients diagnosed using Rome IV criteria with irritable bowel syndrome with constipation are included. The study was approved by the Ethic Committee of the University of Medicine and Pharmacy "Gr. T Popa" Iasi to be conducted at the Institute of Gastroenterology and Hepatology of Clinical Emergency Hospital "Sf. Spiridon" Iasi. The patients are assigned after a randomized scheme to one of the groups: diet restriction scheme or diet restriction scheme plus a product with inuline, choline and silymarin. After 28 days the patients are crossed between the groups and followed for additional 28 days diet scheme with or without inuline, choline and silymarin supplementation. All the patients are evaluated initially, in the day 28 and in the day 57 for the stool habits, stool characteristics using Brystol Scale and symptoms severity (abdominal pain, frequency of abdominal pain, bloating severity, patients satisfaction in relation with stool frequency and the impact of IBS on daily activity) as appreciated by the patients for the last 10 days.

The acquired data will be analyzed and published.
The invention discloses a traditional Chinese medicine treatment and health-care product, belonging to the traditional Chinese medicine and pharmacology field, relates to a traditional Chinese medicine pillow for treating sterility. The traditional Chinese medicine pillow comprises: bupleurum root, nutagrass flatsedge rhizome, chinaberry fruit, mint, curcuma root, peony root, angelica, white peony root, prepared rehmannia rhizome, Chinese yam or the like which are prepared by weight part. The pillow is capable of nourishing the yin and tonifying the blood, dispersing the depressed vital energy, rearing unicorn and has better health-care function capable of relieving pressure and relaxing mind for sterility due to liver-stagnation kidney (yin) deficiency. The pillow not only saves medicines, but also prevents administration difficulty. The pillow creates excellent economical treatment environment for the patient without pain, the patient can be treated just in bed rest. The pillow has features of safety, stability, no side effect, wide foreground, further development value.
BACKGROUND: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine illnesses. There is evidence that exercise training positively affects on improvement of the pathogenic factors in women with PCOS. On the other hand, some studies reported similar effects of aerobic and resistance exercises or no effect of exercises on the improvement of the pathogenic factors. The aim of the current study was to perform a network meta-analysis of RCTs to evaluate the efficacy of exercises on body mass index (BMI), hormone concentrations, and regular menstruation in women with PCOS.
METHODS: The search was performed from databases of PubMed, Scopus, and Web of Science with the keywords of exercise, resistance exercise, aerobic exercise, endurance exercise, yoga, polycystic ovary syndrome, randomized controlled trial based on the CONSORT, BMI, sex hormone and regular menstruation from inception until April 15, 2022. Bayesian random-effects network meta-analyses were performed to calculate mean difference and 95% credible intervals.
RESULTS: Out of 1140 studies, 19 were eligible for inclusion. The results showed that moderate-intensity aerobic exercise effectively reduces BMI compared to no intervention and Yoga. No other forms of exercise led to weight loss. Additionally, exercise had no impact on sex hormones and regular menstruation. It was concluded that moderate-intensity aerobic exercise is the most effective for reducing BMI in women with PCOS.
CONCLUSIONS: Due to the limitations regarding the small sample size and lack of subgroup and sensitivity analysis, the results of this study demonstrated that moderate-intensity, aerobic exercise is the most effective exercise for reducing BMI, while the other exercises were ineffective. Moderate-intensity aerobic exercise is suggested to decrease the BMI in women with PCOS.
SYSTEMATIC REVIEW REGISTRATION: This systematic review and network meta-analysis study was registered in PROSPERO (CRD42022324839).
The system provides a method and apparatus for patient monitoring. In one embodiment, the system comprises beacons located in the patient environment. The beacons may be part of the Medical Internet of Things (MIOT). The patient has a medical wearable that includes fall detection and non-clinical medical monitoring within a geo-fencing perimeter to assure patient safety. The caregivers wear monitoring badges that identify the location, proximity, time management and resources spent for a patient. A central hub base station in the home coordinates and collects the information from the beacons, badges, and medical wearable to deliver information (e.g., via the cloud) for the management of the patient and the caregiver.
According to the US Vital Health Statistics report, acute pharyngotonsillitis is responsible for more than 6 million office visits each year by children younger than 15 years of age. Approximately 30% of cases is of bacterial etiology and group A beta-hemolytic streptococci(GABHS) are responsible for most bacterial cases, although other pathogens, such as Neisseria gonorrhoeae, Arcanobacterium haemolyticum, Mycoplasma pneumoniae, and Chlamydia pneumoniae, may be the causative agents in sporadic cases. An accurate diagnosis of GABHS infection is important because it is the only common form of acute pharyngotonsillitis for which antibiotic therapy is definitely indicated. Effective antibacterial treatment can shorten the clinical course of GABHS pharyngotonsillitis, reduce the rate of transmission, and prevent suppurative and nonsuppurative complications, such as peritonsillar abscess and acute rheumatic fever.

This study enrolls patients who will present with acute fever and clinical signs of pharyngotonsillitis at three primary pediatric ambulances. A rapid A beta-hemolytic streptococcus (GABHS)-detection test will be performed in these patients. In one office, additional throat cultures are obtained of all patients, and blood is taken in a subgroup of 60 GABHS-positive and 60 GABHS-negative cases. In GABHS-positive patients, a second blood sample will be obtained at day 7th and day 28th, and stored until specific antibody response to GABHS will be measured.
The exercise intervention will utilize the "Moving Through Cancer: A Guide to Exercise for Cancer Survivors" framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises).
There is abundant literature reporting about the use of antibiotics in inflammatory bowel disease (IBD), but their role in the management of IBD is not entirely clear. Diverse infectious organisms have been implicated in the pathogenesis of Crohn's disease. Also, infections are believed to be a trigger for flares of ulcerative colitis. The benefit of the routine use of antibiotics in IBD is equivocal. However, there are certain situations, where antibiotics have a clear role and evidence of benefit: perianal fistula, intra-abdominal abscesses in Crohn's disease, acute pouchitis and infection-related flares. However, there is a lack of supportive evidence for the routine use of antibiotics in all disease-related flares. Evidence indicates a lack of benefit of intravenous antibiotics in acute severe ulcerative colitis and only limited benefit in active ulcerative colitis. Limited evidence suggests the role of a combination of oral antibiotics in pediatric ulcerative colitis. Certain targeted antibiotic regimens have been used in IBD. In ulcerative colitis, limited evidence suggests the benefit of the use of an antibiotic cocktail directed against Fusobacterium varium. Therapy directed against Escherichia coli does not seem to have a benefit in inflammatory Crohn's disease. In Crohn's disease, antimycobacterial therapy may result in symptomatic improvement but no durable benefit. Antitubercular therapy (ATT), on the contrary, may result in fibrotic transformation, suggesting a need to avoid misdiagnosis and limit the duration of ATT in Crohn's disease. This review assesses the published literature with respect to antibiotic use and provides guidance to clinicians in appropriate antibiotic use in various situations in the setting of IBD.
The invention discloses a novel dosage form containing albendazole and application and a preparation method thereof. The novel dosage form mainly takes the mixture of albendazole and pamoic acid pyrantel as a medicinal composition, and an excipient and a flavoring agent are added to the medicinal composition to be made into granules. The novel dosage form contains 500-800 parts of medicinal composition, 40-120 parts of excipient and 50-100 parts of flavoring agent in parts by weight. The granules have the advantages of good drug disperse states, short disintegration time, rapid drug dissolution, rapid absorption, high bioavailability and the like and are convenient to take. The drug mouthfeel can be regulated according to the fondness of children, such as the apple taste, the lemon taste and the like. The novel dosage form is especially suitable for children, patients with special conditions and patients who are difficult to swallow. However, the children are parasitic disease susceptible populations but have poorer drug compliance. In order to increase the drug compliance of the children and improve the drug mouthfeel and the taking mode, designing the dosage form into the granules is extremely necessary. The invention also makes the orally taken dosage form of the compound albendazole granules diversified and simultaneously provides more selections for clinician and patient medications.
The invention discloses a radix puerariae and red date electuary and a preparation method thereof and belongs to the technical field of food. The radix puerariae and red date electuary comprises the following raw materials in parts by weight: 600-660 parts of radix puerariae starch, 200-300 parts of Chinese yam, 200-300 parts of polygonatum rhizome, 200-300 parts of red date, 200-300 parts of lotus seed and 350-400 parts of glucose. According to the technical scheme of the invention, radix puerariae powders are adopted as the main material of the electuary. Meanwhile, Chinese yam, polygonatum rhizome, red date, lotus seed and other Chinese herbal medicines, which are served as both food and medicine, are adopted as the auxiliary materials of the electuary. Therefore, the electuary has the advantages of nourishing the Yin, moistening the dryness, descending the Qi nourishing a human body, regenerating the body fluid, embellishing a lung, nourishing a stomach, dispelling the effects of alcohol, relieving the cholesterol, nourishing the Zhong, descending the Qi, invigorating the spleen and the Qi, clearing away the heat, detoxifying, promoting the production of the body fluid to relieve the thirst, inducing the diuresis and relaxing the bowel. At the same time, the electuary does not contain any anti-microbial agent, preservative or other chemical additives. Therefore, the electuary is natural, environmentally friendly and free of any toxic and side effect.
A pharmaceutical formulation comprising polymeric nanoparticles encapsulated within cross-linked polymeric microparticles is provided wherein the polymeric nanoparticles carry a therapeutic agent suitable for the treatment of pulmonary arterial hypertension (PAH) loaded within them, for use in the treatment of PAH. The polymeric nanoparticles may comprise a chitosan; a chitosan-derivative polymer selected from chitosan-PEG, N-trimethyl chitosan or a derivative of chitosan comprising a stearic acid, cholanic acid, phthaloyl or butyl acrylate side chain; poly(lactic-co-glycolic acid); or a self-assembly amphiphilic chitosan derivative selected from chitosan-PEG-cholanic acid, chitosan-PEG-stearic acid or chitosan-PEG-oleic acid. Preferably the cross-linked polymeric microparticles are cross-linked hydrogel polymeric microparticles that are pH responsive and comprise self-interpenetrating polymeric networks (semi-IPNs) or full-IPNs. Preferably the cross-linked polymeric micrparticles comprise chitosan or a water soluble chitosan derivative, such as carboxymethyl and PEGylated derivatives. Preferably the microparticles further comprise one or more polymers selected from hyaluronate, carrageenan and oligoguluronate. Preferably the therapeutic agent is selected from prostacyclin synthetic analogues, PPAR Î² agonists and NO donors, in particular the therapeutic agent is a protacyclin synthetic analogue selected from treprostinil or selexipag. Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.
Norepinephrine (sometimes referred to as l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic amine which differs from epinephrine by the absence of a methyl group on the nitrogen atom.

Norepinephrine Bitartrate is (-)-α-(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate (molecular weight 337.3 g/mol) and has the following structural formula:

  
Norepinephrine Bitartrate Injection, USP is supplied in a sterile aqueous solution in the form of the bitartrate salt to be administered by intravenous infusion. Norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids. Each mL contains 1 mg of norepinephrine base (equivalent to 1.89 mg of norepinephrine bitartrate, anhydrous basis), sodium chloride for isotonicity, not more than 0.2 mg (vials) of sodium metabisulfite as an antioxidant. It has a pH of 3.0 to 4.5. The air in the containers has been displaced by nitrogen gas.
Cytoprotection has emerged as an effective therapeutic strategy for mitigating brain injury following acute ischemic stroke (AIS). The sulfonylurea receptor 1-transient receptor potential M4 (SUR1-TRPM4) channel plays a pivotal role in brain edema and neuroinflammation. However, the practical use of the inhibitor glyburide (GLB) is hindered by its low bioavailability. Additionally, the elevated reactive oxygen species (ROS) after AIS exacerbate SUR1-TRPM4 activation, contributing to irreversible brain damage. To overcome these challenges, GLB and superoxide dismutase (SOD) were embedded in a covalent organic framework (COF) with a porous structure and great stability. The resulting S/G@COF demonstrated significant improvements in survival and neurological functions. This was achieved by eliminating ROS, preventing neuronal loss and apoptosis, suppressing neuroinflammation, modulating microglia activation, and ameliorating blood-brain barrier (BBB) disruption. Mechanistic investigations revealed that S/G@COF concurrently activated the Wnt/β-catenin signaling pathway while suppressing the upregulation of SUR1-TRPM4. This study underscores the potential of employing multi-target therapy and drug modification in cytoprotective strategies for ischemic stroke.
BACKGROUND: Intraoperative hemorrhage in cardiac surgery increases risk of morbidity and mortality. Low pre-operative and perioperative levels of fibrinogen, a key clotting factor, are associated with severity of hemorrhage and increased transfusion of blood components. The ability to supplement fibrinogen during hemorrhagic resuscitation is delayed 45-60 min because cryoprecipitated antihemophilic factor (cryo AHF) is stored frozen, due to a short post-thaw shelf life. Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) can be kept thawed, at room temperature, for up to 5 days, making it possible to be immediately available for hemorrhaging patients. This trial will investigate if earlier correction of acquired hypofibrinogenemia with IFC in hemorrhaging cardiac surgery patients reduces the total number of perioperatively transfused allogeneic blood products (red blood cells, plasma, and platelets) as compared to cryo AHF.
METHODS: This is a single center, prospective, cluster randomized trial with an adaptive design. Acquired hypofibrinogenemia will be assessed by rotational thromboelastometry (ROTEM) and the threshold for cryo AHF/IFC transfusion defined as FIBTEM A10 ≤ 10 mm in bleeding patients. IFC/cryo AHF will be randomized by 1-month blocks. Cardiac surgery patients will be enrolled in the study if they have an eligible procedure and at least one dose of a cryo AHF/IFC product (approximately 2 g fibrinogen) is transfused. Data from the electronic health record, including the blood bank and lab information systems, will be prospectively collected from the health system's data warehouse.
DISCUSSION: This trial aims to provide evidence of the clinical efficacy of utilizing readily available thawed IFC during acute bleeding in the cardiac surgery setting compared to traditional cryo AHF.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05711524. Feb 3, 2023.
BACKGROUND: Fatigue is a prominent symptom of heart failure (HF). However, underlying mechanisms remain poorly understood. Fluid volume status has been suggested as a physiologic mechanism of HF-related fatigue. Serum osmolality may fluctuate with changes in volume status associated with neurohormonal dysregulation. The relationship of fatigue to serum osmolality has not been assessed in adults with HF.
OBJECTIVES: Describe the relationship between serum osmolality and fatigue in adults with HF.
METHODS: We analyzed two waves of cross-sectional data from the National Health and Nutrition Examination Survey (2015-2016 and 2017-2018). Adults who self-reported having HF without select co-morbid conditions known to contribute to fatigue were included. Data were weighted to provide US national estimates, and complex sample design used for analyses. Sequential logistic regression was used to isolate the effect of serum osmolality on the odds of having fatigue.
RESULTS: Data from the sample represented 1.4 million Americans with HF (58.5 % male; median age 68 years), of whom 1,001,589 (67.9 %) reported fatigue. Participants with fatigue had lower serum osmolality compared to those without fatigue (t = -3.04, p = .009). Higher serum osmolality was associated with 8.8 % lower odds of experiencing fatigue when controlling for sex and body mass index (OR = 0.912, p = .007, CI 0.857 - 0.972).
CONCLUSIONS: HF-related fatigue is associated with lower serum osmolality. Low serum osmolality may indicate excess volume and the presence of a heightened neurohormonal response, both of which may influence fatigue. Alternatively, serum osmolality may directly affect other physiologic changes that may contribute to fatigue.
PURPOSE: To obtain a D-glucan/protein conjugate showing excellent actions of ameliorating the liver function and stimulating the appetite, and other actions by subjecting the precipitates from the solution of an extract from Aqaricus blazei to an anion-exchange treatment and forming a protein conjugate in the watery eluate. CONSTITUTION: The fruit bodies or mycelia of Aqaricus blazei or a ground or dried product thereof is extracted with hot water. The obtained extract is subjected to a precipitation treatment with a polar organic solvent to form precipitates, which are subjected to an anion-exchange treatment to form a β-(1 to 6):β(1 to 3)-D-glucan/protein conjugate in the watery eluate. This conjugate has an average molecular weight (gel filtration method, in terms of dextran) of 30000-50000, a sugar content (phenol/sulfuric acid method, in terms of glucose) of 60.2±10.9wt.%, and a sugar composition of 100 pts.wt. glucose, 5.2±2.5 pts.wt.galactose, 4.1±1.5 pts.wt. mannose and traces of fucose, xylose, arabinose and ribose.
Patients with mean arterial pressure \<100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.